[Digital health applications in urology].

IF 0.4 4区 医学 Q4 UROLOGY & NEPHROLOGY Urologie Pub Date : 2024-09-01 Epub Date: 2024-08-12 DOI:10.1007/s00120-024-02398-0
Sandra Schönburg, Christian Gratzke, Kurt Miller, Laura Wiemer, Sabine Kliesch
{"title":"[Digital health applications in urology].","authors":"Sandra Schönburg, Christian Gratzke, Kurt Miller, Laura Wiemer, Sabine Kliesch","doi":"10.1007/s00120-024-02398-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Digital health applications (DiGA) were included in the German healthcare system in 2020. They are available for prescription and reimbursed by public and private insurance companies. For the specialty of urology, there are currently two DiGA available: for the treatment of erectile dysfunction and benign prostatic hyperplasia/overactive bladder (BPH/OAB). The legal basis, clinical results and practical implementation are presented.</p><p><strong>Methods: </strong>Evaluation of websites and publications to show the regulatory requirements, mode of action, results of clinical trials and prescribing practice with DiGA.</p><p><strong>Results: </strong>Since 2020, 63 DiGA have been listed in the register of the Federal Office for Drugs and Medical Devices (BfArM), 35 of them definitively. Two urological DiGA aim to treat erectile dysfunction and BPH/OAB. Randomized, controlled studies have shown a significant and clinically relevant patient benefit for both DiGA. Further urological DiGA are in clinical development.</p><p><strong>Conclusions: </strong>DiGAs offer multimodal therapy combinations that have not yet been used in clinical practice and show a multidimensional benefit for the patient.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"850-859"},"PeriodicalIF":0.4000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00120-024-02398-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/12 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Digital health applications (DiGA) were included in the German healthcare system in 2020. They are available for prescription and reimbursed by public and private insurance companies. For the specialty of urology, there are currently two DiGA available: for the treatment of erectile dysfunction and benign prostatic hyperplasia/overactive bladder (BPH/OAB). The legal basis, clinical results and practical implementation are presented.

Methods: Evaluation of websites and publications to show the regulatory requirements, mode of action, results of clinical trials and prescribing practice with DiGA.

Results: Since 2020, 63 DiGA have been listed in the register of the Federal Office for Drugs and Medical Devices (BfArM), 35 of them definitively. Two urological DiGA aim to treat erectile dysfunction and BPH/OAB. Randomized, controlled studies have shown a significant and clinically relevant patient benefit for both DiGA. Further urological DiGA are in clinical development.

Conclusions: DiGAs offer multimodal therapy combinations that have not yet been used in clinical practice and show a multidimensional benefit for the patient.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[泌尿外科的数字健康应用]。
背景:数字医疗应用程序(DiGA)于 2020 年被纳入德国医疗系统。这些应用程序可用于处方,并由公共和私营保险公司报销。在泌尿外科专业,目前有两种 DiGA 可用:用于治疗勃起功能障碍和良性前列腺增生/膀胱过度活动症(BPH/OAB)。本文介绍了其法律依据、临床结果和实际执行情况:方法:对网站和出版物进行评估,以了解 DiGA 的法规要求、作用方式、临床试验结果和处方实践:结果:自 2020 年以来,63 种 DiGA 已被列入联邦药品和医疗器械管理局(BfArM)的登记册,其中 35 种已确定。两种泌尿科用 DiGA 旨在治疗勃起功能障碍和良性前列腺增生/尿道狭窄。随机对照研究表明,这两种 DiGA 都能为患者带来显著的临床相关益处。更多泌尿科 DiGA 正在临床开发中:结论:DiGA 提供了尚未在临床实践中使用的多模式疗法组合,为患者带来了多方面的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Urologie
Urologie UROLOGY & NEPHROLOGY-
CiteScore
1.00
自引率
0.00%
发文量
0
期刊最新文献
[Cystic renal masses: Active treatment or surveillance? Translation and discussion of a systematic literature review with meta-analysis]. [The central role of nurses in detection and management of symptoms in patients with urologic cancer]. [The OPTIMUM trial: microultrasonography-guided vs MRI-guided biopsy for prostate cancer diagnosis]. [Criminal risks associated with patient treatment-documentation and informed consent obligations]. [Diagnosis and treatment of urothelial carcinoma of the bladder with divergent histology].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1